Loading…
Company moves forward with next steps in clinical evaluation.
NanoVibronix announced the completion of the pilot phase of its clinical study evaluating UroShield, a non-invasive surface acoustic wave therapy device, at the University of Michigan. The study aimed to assess the device's efficacy in reducing urinary tract infections in patients with long-term indwelling Foley catheters.
The company did not report specific amounts or outcomes from the pilot phase. NanoVibronix will now proceed with further clinical evaluations to gather additional data on UroShield's performance.
As of the latest available data, NanoVibronix has a free float of 1,088,100 shares and 1,088,200 shares outstanding.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.